NCT02344849 is a Phase 1 clinical trial of mesenchymal stem cell in Erectile Dysfunction, sponsored by Pharmicell Co., Ltd..

Who is sponsoring NCT02344849?

NCT02344849 is sponsored by Pharmicell Co., Ltd..

What drugs are being tested in NCT02344849?

Interventions in NCT02344849: mesenchymal stem cell.

What condition does NCT02344849 study?

NCT02344849 studies Erectile Dysfunction.

Is NCT02344849 still recruiting?

NCT02344849 is currently completed. Last updated 7 January 2019.

Last reviewed 2019-01-07 · How we verify

NCT02344849

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Open, Single-center, Phase 1 Study to Evaluate Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Erectile Dysfunction.

Completed Phase 1 Last updated 7 January 2019

What this trial tests

Phase 1 trial testing mesenchymal stem cell in Erectile Dysfunction in 10 participants. Completed in 1 April 2018.

Timeline

1 July 2015

Primary endpoint
31 January 2018

1 April 2018

Quick facts

Lead sponsor	Pharmicell Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	1 July 2015
Primary completion	31 January 2018
Estimated completion	1 April 2018
Sites	1 location across South Korea

Drugs / interventions tested

mesenchymal stem cell

Conditions studied

Erectile Dysfunction — all drugs for Erectile Dysfunction →

Sponsor

Pharmicell Co., Ltd. — full company profile →

Who can join

20 and older, male only, with Erectile Dysfunction. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number and severity of adverse events
Time frame: 12month
Analyze the laboratory, vital sign, physical exam results from baseline to end of the study for investigate adverse reactions and view safety. An SAE suggests a significant hazard, contraindication, side-effect, or precaution. With respect to human clinical experience, this includes any event that: Results in death. Is life-threatening.\* Requires in-patient hospitalization or prolongation of ex

Sponsor's own description

This phase I clinical trial is designed to evaluate the safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Mesenchymal stromal/stem cells and their exosomes for restoration of spermatogenesis in non-obstructive azoospermia: a systemic review.
Zhankina R, Baghban N, Askarov M, Saipiyeva D, et al · · 2021 · cited 49× · PMID 33823925 · DOI 10.1186/s13287-021-02295-9
The Clinical Trials of Mesenchymal Stromal Cells Therapy.
Kouchakian MR, Baghban N, Moniri SF, Baghban M, et al · · 2021 · cited 30× · PMID 34745268 · DOI 10.1155/2021/1634782
Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial.
You D, Jang MJ, Song G, Shin HC, et al · · 2021 · cited 26× · PMID 34326007 · DOI 10.1016/j.jcyt.2021.06.001
Recent advances in stem cell therapy for erectile dysfunction: a narrative review.
Wang B, Gao W, Zheng MY, Lin G, et al · · 2023 · cited 10× · PMID 37078259 · DOI 10.1080/14712598.2023.2203811
Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time?
Bonanni M, Rehak L, Massaro G, Benedetto D, et al · · 2022 · cited 7× · PMID 35625828 · DOI 10.3390/biomedicines10051091
Expert Consensus on Prevention and Treatment of Aging-Related Gonadal Dysfunction.
Wang X, Ma L, Jiang S, Wen J, et al · · 2024 · cited 2× · PMID 38739936 · DOI 10.14336/ad.2024.0004
Interrogating erectile dysfunction and evaluating novel therapeutic frontiers, with emphasis on stem cell strategies.
Sonawane T, Kashte S, Khera S, Bahulkar A, et al · · 2024 · cited 1× · PMID 39023828 · DOI 10.1007/s10815-024-03165-y

Verify or expand the search:

Other trials of mesenchymal stem cell

Trials testing the same drug.

NCT05939167 — Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage · Phase 1, PHASE2 · recruiting
NCT03209986 — Trial of Mesenchymal Stem Cell Transplantation in Decompensated Liver Cirrhosis · NA · unknown

Other recruiting trials for Erectile Dysfunction

Currently open trials in the same condition.

NCT07442396 — The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation · NA · recruiting
NCT07366970 — Is There a Benefit From Addition of Exercise in Diabetic Patients With ED Who Complain Low Vitamin D? · NA · recruiting
NCT06960746 — Changing Lifestyle in OSA Males Who Suffer Metabolic Syndrome and Impotence: Is There a Response? · NA · recruiting
NCT06872866 — The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under · Phase 1 · recruiting
NCT06805513 — Actual Use Trial of Tadalafil 5 mg · Phase 3 · recruiting

Other Pharmicell Co., Ltd. trials

Trials by the same sponsor.

NCT07431008 — Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction · recruiting
NCT07400458 — Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration · NA · recruiting
NCT05042206 — Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease · Phase 1 · completed
NCT05093881 — Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study · NA · recruiting
NCT04615845 — Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC) · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02344849 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pharmicell Co., Ltd.
Last refreshed: 7 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02344849.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing